Mice vaccinated with mycobacterial ribonucleic acid (RNA) produced a high immune response and did not develop delayed hypersensitivity to purified protein derivative (PPD), and rifampin had no effect on the immune response. Mice vaccinated with viable H37Ra cells produced a high immune response and did develop delayed hypersensitivity to PPD. Rifampin had no effect on this immune response, but reduced the footpad reactions to PPD. Both mycobacterial RNA and poly(A:U) served as adjuvants for induction of hypersensitivity to PPD. This hypersensitivity was reduced by the administration of rifampin. Rifampin had no effect on the production of mycobacterial growth inhibitory factor, which is produced following vaccination of mice with mycobacterial RNA or viable H37Ra cells. Rifampin had no effect on the nonspecific phase of the granulomatous response, but did inhibit the secondary allergic phase of this response. The action, therefore, ofrifampin that inhibits the induction ofdelayed hypersensitivity but has no effect on the immune responses against tuberculosis leads to a separation of tuberculin hypersensitivity from cellular immunity to tuberculosis.
Rifampin has been shown to suppress the formation of antibody (1, 11, 13, 19) , to be a very effective antimycobacterial drug (10, 19) , and to suppress the reaction of purified protein derivative (PPD) in guinea pigs vaccinated with Freund complete adjuvant (3) . We have found that rifampin has no effect on the immune response produced in mice vaccinated with our mycobacterial ribonucleic acid (RNA) vaccine (19) . Mice and guinea pigs vaccinated with ribosomal or RNA vaccines do not develop tuberculin hypersensitivity (5, 24) , nor do their lymphocytes produce migration inhibitory factor when stimulated with PPD. The results of these studies indicate that delayed hypersensitivity to PPD and cellular immunity to tuberculosis are dissociable entities. Further experiments using rifampin, as will be seen, support this conclusion.
MATERIALS AND METHODS
Animal experiments. Male inbred C57BV/6 mice were obtained from the Jackson Laboratory, Bar Harbor, Me. When used, they weighed between 18 to 22 g and were housed 10 to a cage. The mice were vaccinated intraperitoneally, held for 4 weeks, and then challenged intravenously with 1.0 mg of the highly virulent strain H37Rv of Mycobacterium tuberculosis (21) . Survival time was measured by a daily inspection of the cages, and the time of death of each mouse was recorded. After 30 days, the surviving mice were killed, since by that time most or all of the control, nonvaccinated mice were dead, and the percentage of survival of each group was determined. The reliability and validity of the above procedures for measurement of the immune response of mice has been published previously (21) .
Vaccines. The mycobacterial RNA was prepared by the method we have previously described (14, 17) and was used within 3 days after preparation. Just before vaccination, it was incorporated into Freund incomplete adjuvant (15) . The viable cells from which the mycobacterial RNA vaccine was prepared were of the attenuated strain, H37Ra, of M. tuberculosis. These cells were used, in addition, as a control for the mycobacterial RNA vaccine. The manner in which we maintain and grow these cells has been described by us in detail (16 (4, (6) (7) (8) 12 (22) . A granulomatous index can be calculated by dividing the mean weight of the lungs of the injected mice by the mean weight of the lungs of the nonijected control mice (22) .
RESULTS
The effect of rifampin on the immune response obtained in mice vaccinated with mycobacterial RNA and viable H37Ra cells is shown in Table 1 . Mice vaccinated with mycobacterial RNA were protected against tuberculosis and had negative footpad reactions to PPD. Treatment with rifampin had no effect on the immune response. Mice vaccinated with the viable H37Ra cells also were protected against tuberculosis, and these mice had strong footpad reac- given ( c Given in the drinking water.
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untreated with rifampin. However, the H37Ra-vaccinated mice in which treatment was started 2 days before vaccination had a lower or no immune response, but if the treatment was delayed until 10 days after vaccination the rifampin had no effect on the immune response. This suggests that the H37Ra cells had sufficient time to be phagocytized, liberate their RNA, and immunize against tuberculosis. Even though the rifampin was started 10 days after vaccination, it still significantly reduced tuberculin hypersensitivity.
Since mycobacterial RNA has doublestranded characteristics (18) , mice were injected intraperitoneally with mycobacterial RNA that had been mixed with PPD to determine whether the adjuvant action of mycobacterial RNA (2, 25) might produce a footpad reaction to PPD. PPD injected alone does not induce tuberculin hypersensitivity. The results ofthese experiments are shown in Table 3 . The mice vaccinated with a mycobacterial RNA-PPD mixture developed tuberculin hypersensitivity, as indicated by the strong footpad reactions. The induction of this hypersensitivity, however, was completely suppressed by treatment with rifampin, but the immunogenic activity of the mycobacterial RNA again was not affected by treatment with rifampin, whether PPD was given or not. The synthetic double-stranded polyribonucleotide, poly(A:U), was substituted for mycobacterial RNA and mixed with PPD (2) to determine whether it would act as an adjuvant for PPD to produce a positive footpad reaction to PPD. The mice vaccinated with poly(A:U) mixed with PPD did develop positive footpads, and these were reduced in a similar group of vaccinated mice treated with rifampin (Table 3) . Experiments also were done to test the effect of rifampin on the production of mycobacterial growth inhibitory factor. This is a lymphocyte product which will inhibit the intracellular growth of virulent tubercle bacilli (4, (6) (7) (8) 12 ). Table 4 shows results which indicate that rifampin did not inhibit the formation of mycobacterial growth inhibitory factor; in fact, it seemed to increase the amount of inhibition. These findings suggest again that cellular immunity and the production of tuberculin hypersensitivity are not related.
Finally, the effect of rifampin on the pulmonary granulomatous response in mice induced by the intravenous injection of 5.0 mg of viable H37Ra cells was determined, and this is shown in Fig. 1 . Rifampin had no effect on the nonspecific rise of the granulomatous response that occurred at day 2, but it did inhibit the specific allergic granulomatous response to the H37Ra cells, which began approximately 23 days after vaccination. At day 23 there was a slight rise in the lung weights of the treated VOL. 13, 1976 on October 11, 2017 by guest http://iai.asm.org/ Downloaded from mice, which correlated with the high rise in the lung weights from the nontreated mice; however, by day 30 the lung weights in the treated mice were again reduced. At day 30 treatment with rifampin was stopped, and the remaining mice were held for approximately 4 weeks to determine whether during this time the lungs of the formerly treated mice would eventually increase in size and be comparable to the nontreated mice. Weights of the lungs of the treated mice increased slightly by day 56, but then began decreasing, as did the lungs from the nontreated mice, so that by day 62 the weights of the lungs of the two groups were almost identical (Fig. 1) . Shown in Table 5 is a summary of our results comparing the effect ofrifampin on the immune response to mycobacterial RNA and viable H37Ra cells, on delayed hypersensitivity, on mycobacterial growth inhibitory factor production, and on the granulomatous response. We found that (i) mice vaccinated with mycobacterial RNA produced a high immune response and did not develop delayed hypersensitivity to PPD, and rifampin had no effect on the immune response.
(ii) Mice vaccinated with viable H37Ra cells produced a high immune response and did develop delayed hypersensitivity to PPD. Rifampin had no effect on this immune response, but it reduced the footpad reactions to PPD. (iii) Both mycobacterial RNA and poly-(A:U) served as adjuvants for induction of hypersensitivity to PPD. This hypersensitivity was reduced by the administration of rifampin. (iv) Rifampin had no effect on the production of mycobacterial growth inhibitory factor, which is produced after vaccination of mice with RNA or H37Ra cells. (v) Finally, rifampin had no effect on the nonspecific phase of the granulomatous response, but it did inhibit the secondary allergic phase of this response.
Therefore, the action of rifampin, which inhibits the induction of delayed hypersensitivity but has no effect on the immune responses against tuberculosis, leads to a separation of tuberculin hypersensitivity from cellular immunity to tuberculosis. DISCUSSION The differential effect of rifampin on the induction of immunity to tuberculosis and on the induction of tuberculin hypersensitivity is difficult to explain if, as is commonly believed, both are T lymphocyte-mediated phenomena. There is some reason to think that different T lymphocyte populations may be involved in the two phenomena (9, 20) . If this should be the case it is conceivable that rifampin might inhibit deoxyribonucleic acid-dependent RNA polymerase activity in those T lymphocytes responsible for delayed-type hypersensitivity, but be unable to do so, for unknown reasons, in those T lymphocytes responsible for immunity to infection. On the other hand, it is possible that rifampin in both cases does not feature of this immune reaction. Therefore, since the in vivo immune reactions are so different, rifampin might well affect the primary cell involved in the tuberculin reaction, i.e., the lymphocyte, and not affect the primary cell involved in the inhibition of multiplication of virulent tubercle bacilli, i.e., the macrophage.
Further experimentation will be required to resolve these matters, or, perhaps, further experimentation will reveal some entirely different explanation for the differential effect of this immunosuppressive drug on the two immune responses. In this connection, we have pointed out in another publication (19) the amazing parallel between the effect of certain metabolic inhibitors, including rifampin, upon the replication of the oncogenic RNA viruses and their effect upon the induction of immunity to tuberculosis after vaccination of mice with mycobacterial RNA. To us, this suggested the possibility that mycobacterial RNA might replicate in vivo in a manner similar to the oncogenic RNA viruses and that the immune response is in some way dependent upon this replicative process (19) .
Regardless of the mechanism involved the results obtained in this study with rifampin clearly support the thesis that tuberculin hypersensitivity and immunity to tuberculosis are independent phenomena.
